(1S,2S)-2-[(5-chlorothiophen-2-yl)carbonyl]cyclopropane-1-carboxylic acid | 697258-58-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (1S,2S)-2-[(5-chlorothiophen-2-yl)carbonyl]cyclopropane-1-carboxylic acid
• 英文别名: (1S,2S)-trans-[2-(2-chloro-5-thenoyl)]-cyclopropane-1-carboxylic acid；(1S,2S)-2-(5-chlorothiophene-2-carbonyl)cyclopropane-1-carboxylic acid
• CAS: 697258-58-5
• 化学式: C₉H₇ClO₃S
• 分子量: 230.672
• InChiKey: UFHFCYQQEXIAOX-WHFBIAKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (+)-(1S,2S)-cyclopropane-1,2-dicarboxylic acid monomethyl ester 在 草酰氯 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 23.0h， 生成 (1S,2S)-2-[(5-chlorothiophen-2-yl)carbonyl]cyclopropane-1-carboxylic acid
  参考文献：
  名称：

  [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS

  摘要：

  公开号：

  WO2015047982A3

文献信息

• Halothenoyl-cyclopropane-1-carboxylic acid derivatives
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1424333A1

  公开（公告）日：2004-06-02

  Compounds of formula (I) wherein R is hydroxy, linear or branched C1-C6 alkoxy, phenoxy, benzyloxy, a group -N(R1R2) wherein R1 is hydrogen, linear or branched C1-C4 alkyl, benzyl, phenyl and R2 is hydrogen or linear or branched C1-C4 alkyl, or R is a glycoside residue or a primary alkoxy residue from ascorbic acid, optionally having one or more hydroxy groups alkylated or acylated by linear or branched C1-C4 alkyl or acyl groups; X is a halogen atom and n 1 or 2 are long lasting inhibitors of kynurenine 3-monooxygenase (KMO) and potent glutamate (GLU) release inhibitors.

  公式(I)的化合物 其中 R是羟基，线性或支链C1-C6烷氧基，苯氧基，苄氧基，-N(R1R2)基团，其中R1是氢，线性或支链C1-C4烷基，苄基，苯基，R2是氢或线性或支链C1-C4烷基，或者R是糖苷残基或来自抗坏血酸的初级烷氧基残基，可以选择性地有一个或多个被线性或支链C1-C4烷基或酰基烷基化或酰化的羟基； X是卤素原子，n为1或2，是持久的犬尿氨酸3-单加氧酶(KMO)抑制剂和强效的谷氨酸(GLU)释放抑制剂。
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI FOUNDATION, INC.

  公开号：US20160257674A1

  公开（公告）日：2016-09-08

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化合物，或其药学上可接受的盐或前药。还提供了包含至少一种本文所述的化合物、药学上可接受的盐或前药和一个或多个药学上可接受的载体的制药组合物。本文描述了治疗对KMO活性抑制有反应的某些疾病和障碍的方法，包括向这些患者施用至少一种本文所述的化合物、药学上可接受的盐或前药的数量，有效减少疾病或障碍的症状或迹象。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括将至少一种本文所述的化合物、药学上可接受的盐或前药作为单一活性剂或与一个或多个其他治疗剂联合施用。还提供了筛选能够抑制KMO活性的化合物的方法。
• Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
  申请人：CHDI Foundation, Inc.

  公开号：US10428054B2

  公开（公告）日：2019-10-01

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化合物或其药学上可接受的盐或原药。还提供了包含至少一种本文所述化合物或其药学上可接受的盐或原药以及一种或多种药学上可接受的载体的药物组合物。描述了治疗对抑制 KMO 活性有反应的某些疾病和失调患者的方法，其中包括向此类患者施用一定量的本文所述的至少一种化合物或其药学上可接受的盐或原药，以有效减少疾病或失调的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿氏病。还描述了治疗方法，包括将本文所述的至少一种化合物或其药学上可接受的盐或原药作为单一活性剂给药，或将本文所述的至少一种化合物或其药学上可接受的盐或原药与一种或多种其它治疗剂联合给药。还提供了筛选能够抑制 KMO 活性的化合物的方法。
• US9884853B2
  申请人：——

  公开号：US9884853B2

  公开（公告）日：2018-02-06
• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：CHDI FOUNDATION INC

  公开号：WO2015047982A3

  公开（公告）日：2015-11-19